Mazdutide
Also known as: IBI362, LY3305677
Primary recreational use: Weight loss
What is Mazdutide?
Mazdutide, a synthetic analog of oxyntomodulin, is a first-in-class dual agonist for GLP-1 and glucagon receptors. It is primarily used for weight loss and improving glycemic control in diabetes. Currently, it is in Phase 3 clinical trials and has shown superior results compared to semaglutide in both weight reduction and glycemic control. Users should be cautious of mild to moderate gastrointestinal side effects.
Primary Benefits
Promotes significant weight loss. Improves glycemic control. Reduces liver fat.
How It Works
Mazdutide operates by agonizing both GLP-1 and glucagon receptors, enhancing insulin release while suppressing glucagon. This dual action increases energy expenditure by stimulating thermogenesis and suppresses appetite, collectively leading to weight loss. GLP-1 effects counteract glucagon’s rise in glucose, maintaining glycemic control.
Safety Tips
Precautions reported in community discussions and literature. This is not a complete list.
- 1.DON'T start with the highest dose; begin with the lowest tolerated dose to minimize side effects.
- 2.DON'T mix with sulfonylureas or insulin without monitoring blood glucose carefully.
- 3.AVOID use during pregnancy due to insufficient safety data.
- 4.DON'T rely solely on this peptide without lifestyle changes for metabolic health.
- 5.DON'T inject without rotating sites to avoid irritation.
- 6.NEVER use without confirming source purity due to contamination risks from research chemicals.
- 7.AVOID extreme temperature conditions for storage to prevent degradation.
- 8.DON'T use if you have a history of medullary thyroid carcinoma or MEN2 syndrome.
- 9.AVOID if breastfeeding, as effects are unknown.
Use Contexts
Different purposes have different protocols, dosing, and considerations
Weight loss
strong evidenceMazdutide is studied for its weight loss effects in individuals with obesity, showing significant body weight reductions in clinical trials.
Evidence: Phase 3 trials GLORY-1 and GLORY-2 reported significant weight loss efficacy in obese patients.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Any time of day, with or without food
Notes: Consistent weekly dosing; doses escalate over time based on protocol.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| Weight loss initiation | 1.5mg → 3mg | Once weekly | Subcutaneous injection |
| Weight loss progression | 3mg → 4.5mg | Once weekly | Subcutaneous injection |
| Weight loss optimization | 4.5mg → 6mg | Once weekly | Subcutaneous injection |
| Maximum weight loss | 6mg → 9mg | Once weekly | Subcutaneous injection |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Pancreatitis
Injection-Specific Warnings
- Rotate injection sites to avoid irritation
Storage
Type 2 Diabetes Management
strong evidenceMazdutide is under investigation for glycemic control and weight management in T2D patients, showing promising results.
Evidence: Demonstrated efficacy in improving HbA1c and weight reduction in comparison trials with semaglutide.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Any time of day
Notes: May combine with metformin for enhanced effects.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| T2D management | 3mg | Once weekly | Subcutaneous injection |
| T2D with obesity | 6mg → 9mg | Once weekly | Subcutaneous injection |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Pancreatitis
Injection-Specific Warnings
- Rotate injection sites to avoid irritation
Storage
Harm Reduction Information
Quality Concerns
- Contamination from unreliable sources
- Mislabeling due to research-only availability
Safety Tips
- Use bacteriostatic water and sterile technique for reconstitution
- Monitor blood glucose if combined with insulin or sulfonylureas
- Rotate injection sites
- Start with lower doses for dose escalation
Warning Signs to Stop
- Severe abdominal pain indicating pancreatitis
- Persistent nausea
- Severe gastrointestinal distress
Seek Medical Help Immediately If
- Signs of pancreatitis
- Severe allergic reactions
- Extreme abdominal pain
Frequently Asked Questions
Common questions about Mazdutide
How long until I see effects?
Mazdutide often leads to appetite reduction within the first 1-2 weeks, with weight loss beginning in 2-4 weeks.
What time of day should I take it?
Mazdutide can be taken at any time of day, with or without food, but consistently on the same day each week.
How can I minimize side effects?
Start with the smallest effective dose of Mazdutide and increase gradually to minimize gastrointestinal effects.
Does tolerance develop?
Evidence suggests Mazdutide does not lead to tolerance over typical use cycles, maintaining efficacy for up to 60 weeks.
How should I store it?
Store lyophilized Mazdutide at -20°C and reconstituted solutions between 2-8°C, using within 30 days.
Do I need to cycle it?
Mazdutide is typically used continuously for cycles of 48-60 weeks for full metabolic benefits.
What happens if I miss a dose?
If you miss a Mazdutide dose, take it within 3 days and then continue with your regular schedule.
Is it safe for long-term use?
Mazdutide has shown sustained benefits in trials lasting up to 60 weeks without significant long-term safety issues when monitored.
Reported Combinations
Compounds reported to be used alongside Mazdutide in community discussions
CJC-1295
Enhances growth hormone release for metabolic support.
Ipamorelin
May support recovery and weight management.
BPC-157
Supports healing and gut health.
Reported Interactions
Interactions reported in literature and community discussions.
Monitor for hypoglycemia closely.
Conjunction use requires dose adjustment and monitoring.
Often used together with careful monitoring.
Monitor timing when taken together.
Avoid due to redundancy and risk of adverse effects.
Reconstitution Calculator
100 units = 1 mL
Safety Tips
- Always consult a licensed medical professional for dosing and reconstitution instructions.
- Always double check your units. Mixing up mg and mcg can be very dangerous.
- Make sure to select your syringe type. U-100 and U-50 syringes have different units.
- Ensure you're not adding more BAC than your vial can hold. Most vials have maximum capacities listed.
This calculator is for informational and educational purposes only. It does not provide medical advice, dosing recommendations, or safety determinations. Reference ranges shown are compiled from publicly available sources and are not a substitute for guidance from a licensed healthcare professional.
Legal Status by Region
Regulatory status varies by country
USA
investigational
UK
investigational
EU
investigational
Australia
investigational
Canada
investigational
Explore More Research
Browse our database of peptide research information compiled from published literature and community sources.
Citations
Last updated: October 4, 2023